Journal ArticleDOI
Guidelines for the Management of Rheumatoid Arthritis 2002 Update
TLDR
The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.Abstract:
Rheumatoid arthritis (RA) is a progressive polyarthritis that is responsible for over nine million office visits annually. It is likely that most nurse practitioners will care for one or more patients with RA because approximately 1% of the adult population is affected by this disabling disorder. The guideline reviewed in this month's column describes the recommended care of patients who have been previously diagnosed with RA.read more
Citations
More filters
Journal ArticleDOI
Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice.
Katherine L. Kahn,Catherine H. MacLean,Honghu Liu,Laurence Rubenstein,Andrew L. Wong,Judith O. Harker,Wen-Pin Chen,Diane M. Fitzpatrick,Ken J. Bulpitt,Shana Traina,Brian S. Mittman,Bevra H. Hahn,Harold E. Paulus +12 more
TL;DR: In this paper, a prospective cohort study of change in disease-modifying antirheumatic drugs (DMARD) and/or systemic corticosteroid drug or dose for 568 patients with rheumatoid arthritis (RA) across 6,159 clinical encounters within 12 months to examine how changes in clinical specifications change adherence.
Journal ArticleDOI
Pharmacokinetics and efficacy of low-dose methotrexate in patients with rheumatoid arthritis.
TL;DR: In this paper, the authors evaluated the relationship between the pharmacokinetics of methotrexate (MTX), its efficacy in the treatment of rheumatoid arthritis (RA), and serum folic acid (FA) levels.
Journal ArticleDOI
Are better endpoints and better design of clinical trials needed
TL;DR: An ideal endpoint for trials in rheumatic diseases may be a marker that continually follows short-term changes in the disease process, which would be useful as an endpoint in trials and for supporting treatment decisions in clinical practice.
Journal ArticleDOI
Serum levels of anti-cyclic citrullinated peptide antibodies are associated with a beneficial response to traditional herbal medicine (Kampo) in rheumatoid arthritis.
TL;DR: It is suggested that pretreatment serum levels of ACPA are a useful predictor of a good response to treatment with KER, and a decrease in serum levelsof ACPA may be an adjunctive indicator in predicting the efficacy of this kind of treatment.
Journal ArticleDOI
Efficacy of High‐Throughput Leukocytapheresis for Rheumatoid Arthritis With a Reduced Response to Infliximab
Yukinao Sakai,Saori Sakai,Tomoyuki Otsuka,Dai Ohno,Tsuneo Murasawa,Kazuo Munakata,Kyoichi Mizuno +6 more
TL;DR: Results indicate that LCAP is a useful treatment for RA patients with a reduced response to INF, and all patients had a moderate response according to the European League Against Rheumatism response criteria.
References
More filters
Journal ArticleDOI
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
TL;DR: The revised criteria for the classification of rheumatoid arthritis (RA) were formulated from a computerized analysis of 262 contemporary, consecutively studied patients with RA and 262 control subjects with rheumatic diseases other than RA (non-RA).
Journal ArticleDOI
Measurement of patient outcome in arthritis.
TL;DR: A structure for representation of patient outcome is presented, together with a method for outcome measurement and validation of the technique in rheumatoid arthritis, and these techniques appear extremely useful for evaluation of long term outcome of patients with rheumatic diseases.
Journal ArticleDOI
Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis
Claire Bombardier,Loren Laine,Alise S. Reicin,Deborah R. Shapiro,Ruben Burgos-Vargas,Barry R. Davis,Richard O. Day,Marcos Bosi Ferraz,Christopher J. Hawkey,Marc C. Hochberg,Tore K Kvien,Thomas J. Schnitzer +11 more
TL;DR: In patients with rheumatoid arthritis, treatment with rofecoxib, a selective inhibitor of cyclooxygenase-2, is associated with significantly fewer clinically important upper gastrointestinal events than treatment with naproxen, a nonselective inhibitor.
Journal ArticleDOI
Gastrointestinal Toxicity With Celecoxib vs Nonsteroidal Anti-inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: The CLASS Study: A Randomized Controlled Trial
Fred E. Silverstein,Gerald A. Faich,Jay L. Goldstein,Lee S. Simon,Theodore Pincus,Andrew Whelton,Robert W. Makuch,Glenn M. Eisen,Naurang M. Agrawal,William F. Stenson,Aimee M. Burr,William W. Zhao,Jeffrey D. Kent,James B. Lefkowith,Kenneth M. Verburg,G. Steven Geis +15 more
TL;DR: In this study, celecoxib, at dosages greater than those indicated clinically, was associated with a lower incidence of symptomatic ulcers and ulcer complications combined, as well as other clinically important toxic effects, compared with NSAIDs at standard dosages.
Journal ArticleDOI
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Ravinder N. Maini,E W St Clair,F. C. Breedveld,Daniel E. Furst,Joachim R. Kalden,Michael H. Weisman,Josef S. Smolen,Paul Emery,G Harriman,Marc Feldmann,Peter E. Lipsky +10 more
TL;DR: Infliximab was well-tolerated; withdrawals for adverse events as well as the occurrence of serious adverse events or serious infections did not exceed those in the placebo group.
Related Papers (5)
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more